{"filing":{"accession_number":"0001193125-26-294879","cik":"0001858848","ticker":"TNYA","company_name":"Tenaya Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"tnya-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526294879/tnya-20260629.htm"},"events":[{"id":15965,"run_id":14240,"accession_number":"0001193125-26-294879","anchor_item_number":"1.02","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses termination of a material lease for the Company's Genetic Medicines Manufacturing Center (GMMC Facility), with associated costs of $1.75 million in forfeited security deposit plus $294,200 termination fee. While Item 1.02 typically covers termination of material definitive agreements, this is fundamentally an operational restructuring decision—the Company decommissioned the facility in 2025 to reduce costs and is outsourcing manufacturing to a contract manufacturer. The event is material to investors as it reflects a strategic shift in manufacturing operations and carries quantifiable financial consequences, but does not fit the specific categories of workforce_reduction, ma_activity, or financial_other as precisely as operational_other.","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13899,"accession_number":"0001193125-26-294879","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of a material lease for the Company's Genetic Medicines Manufacturing Center (GMMC Facility), with associated costs of $1.75 million in forfeited security deposit plus $294,200 termination fee. While Item 1.02 typically covers termination of material definitive agreements, this is fundamentally an operational restructuring decision—the Company decommissioned the facility in 2025 to reduce costs and is outsourcing manufacturing to a contract manufacturer. The event is material to investors as it reflects a strategic shift in manufacturing operations and carries quantifiable financial consequences, but does not fit the specific categories of workforce_reduction, ma_activity, or financial_other as precisely as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:01:40.346180+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13899,"accession_number":"0001193125-26-294879","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of a material lease for the Company's Genetic Medicines Manufacturing Center (GMMC Facility), with associated costs of $1.75 million in forfeited security deposit plus $294,200 termination fee. While Item 1.02 typically covers termination of material definitive agreements, this is fundamentally an operational restructuring decision—the Company decommissioned the facility in 2025 to reduce costs and is outsourcing manufacturing to a contract manufacturer. The event is material to investors as it reflects a strategic shift in manufacturing operations and carries quantifiable financial consequences, but does not fit the specific categories of workforce_reduction, ma_activity, or financial_other as precisely as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:01:40.346180+00:00","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-07-02"}]}